Stockomendation Regulatory News Service

RNS For Futura Medical (FUM)

Back to the Futura Medical page.

Block Listing Six Monthly Return

RNS Number : 1043W
Futura Medical PLC
06 December 2019

Block Listing Six Monthly Return

6 December 2019

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

Date: 6 December 2019

Name of applicant:

Futura Medical Plc

Name of scheme:

Unapproved Share Option Scheme

Unapproved Share Incentive Scheme

EMI Share Option Scheme

Period of return:


1 June 2019


30 November 2019

Balance of unallotted securities under scheme(s) from previous return:


Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


Less:  Number of securities issued/allotted under scheme(s) during period:


Equals:  Balance under scheme(s) not yet issued/allotted at end of period:


Number and class of securities originally admitted and the date of admission

USOS Total: 3,882,912

814,424 25 May 2011

1,202,280             8 October 2013

1,466,208             25 May 2017

400,000                30 May 2018


USIS Total: 425,000

425,000                30 November 2018


EMI Total: 7,012,088

1,520,576             25 May 2011

1,467,720             8 October 2013

1,893,792             25 May 2017

790,000                 30 May 2018

1,340,000             30 November 2018




For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Tel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:
Bidhi Bhoma/ Euan Brown

Tel: +44 (0) 20 3100 2000


For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile


Tel: +44 (0) 203 950 9144


Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.


The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension.  FM57 is progressing on track, with headline data expected by the end of 2019.


Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Back to the Futura Medical page.

Daily share tips delivered straight to your pc, tablet & mobile

Join Free Today